Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
|
|
Axsome Therapeutics, Inc. (AXSM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/07/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 5% stake in AXSOME THERAPEUTICS, INC. |
| 07/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder in Adults NEW YORK, July 7, 2023 – Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder in adults. FOCUS is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol or placebo for 6 weeks. The primary endpoint..." |
|
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock NEW YORK, June 30, 2023 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and offering expenses, were $225.0 million. Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its com..." |
|
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/06/2023 |
4
| Saad Mark E (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 5,681 options to buy
@ $74.12, valued at
$421.1k
|
|
| 06/06/2023 |
4
| JEFFS ROGER (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 5,681 options to buy
@ $74.12, valued at
$421.1k
|
|
| 06/06/2023 |
4
| Coleman Mark (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 5,681 options to buy
@ $74.12, valued at
$421.1k
|
|
| 05/08/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/06/2023 |
4
| TABUTEAU HERRIOT (CEO) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 110,032 options to buy
@ $65.32, valued at
$7.2M
Granted 62,400 restricted stock units
@ $0 |
|
| 03/06/2023 |
4
| Jacobson Mark L. (COO) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 41,424 options to buy
@ $65.32, valued at
$2.7M
Granted 23,491 restricted stock units
@ $0 |
|
| 03/06/2023 |
4
| Pizzie Nick (CFO) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 36,246 options to buy
@ $65.32, valued at
$2.4M
Granted 20,554 restricted stock units
@ $0 |
|
| 03/06/2023 |
4
| Murdock Hunter R. (General Counsel) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 29,773 options to buy
@ $65.32, valued at
$1.9M
Granted 16,883 restricted stock units
@ $0 |
|
| 03/06/2023 |
4
| Coleman Mark (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 2,870 options to buy
@ $65.32, valued at
$187.5k
|
|
| 03/06/2023 |
4
| JEFFS ROGER (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 2,082 options to buy
@ $65.32, valued at
$136k
|
|
| 03/06/2023 |
4
| Saad Mark E (Director) has filed a Form 4 on Axsome Therapeutics, Inc.|
Txns:
| Granted 2,224 options to buy
@ $65.32, valued at
$145.3k
|
|
| 02/27/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 0% stake in AXSOME THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| PFM Health Sciences, LP reports a 3.2% stake in Axsome Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 4.6% stake in AXSOME THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 7.9% stake in Axsome Therapeutics Inc. |
|
|
|